A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 7, 2009, Pages 664-675

  Cook, Casey ^a   Petrucelli, Leonard ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Aggregation; Alpha synuclein; DJ 1; Leucine rich repeat kinase 2; Lewy bodies; Parkin; Parkinson's disease; Substantia nigra; Ubiquitin ligase; Ubiquitin proteasome system

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CASEIN KINASE I; CASEIN KINASE II; CASPASE 3; CASPASE 8; DJ 1 PROTEIN; DOPAMINE RECEPTOR STIMULATING AGENT; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN 90; HUNTINGTIN; INTERLEUKIN 1BETA CONVERTING ENZYME; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LEUCINE RICH REPEAT KINASE 2; PARKIN; POLYGLUTAMINE; PRION PROTEIN; PROTEASOME; TAU PROTEIN; TRANSCRIPTION FACTOR NRF2; TYROSINE 3 MONOOXYGENASE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNINDEXED DRUG;

DOPAMINERGIC NERVE CELL; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; MUTATION; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 68649118090     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.01.012     Document Type: Review

References (236)

1. Olanow C.W., Watts R.L., and Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56 11 Suppl 5 (2001) S1-S88
2. Olanow C.W., Perl D.P., DeMartino G.N., and McNaught K.S. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 3 8 (2004) 496-503
3. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95 11 (1998) 6469-6473
4. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 5321 (1997) 2045-2047
5. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 9440 (2004) 1167-1169
6. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 2 (1998) 106-108
7. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 5646 (2003) 841
8. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 2 (2004) 164-173
9. Zaccai J., Brayne C., McKeith I., Matthews F., and Ince P.G. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70 13 (2008) 1042-1048
10. Dickson D.W., Fujishiro H., DelleDonne A., Menke J., Ahmed Z., Klos K.J., et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 115 4 (2008) 437-444
11. Hershko A., and Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67 (1998) 425-479
12. Heinemeyer W., Kleinschmidt J.A., Saidowsky J., Escher C., and Wolf D.H. Proteinase yscE, the yeast proteasome/multicatalytic-multifunctional proteinase: mutants unravel its function in stress induced proteolysis and uncover its necessity for cell survival. EMBO J. 10 3 (1991) 555-562
13. Schwartz A.L., and Ciechanover A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med. 50 (1999) 57-74
14. Giasson B.I., and Lee V.M. Are ubiquitination pathways central to Parkinson's disease?. Cell 114 1 (2003) 1-8
15. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., and Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev., Neurosci. 2 8 (2001) 589-594
16. Kopp F., Hendil K.B., Dahlmann B., Kristensen P., Sobek A., and Uerkvitz W. Subunit arrangement in the human 20S proteasome. Proc. Natl. Acad. Sci. U. S. A. 94 7 (1997) 2939-2944
17. Dick T.P., Nussbaum A.K., Deeg M., Heinemeyer W., Groll M., Schirle M., et al. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J. Biol. Chem. 273 40 (1998) 25637-25646
18. Kisselev A.F., Akopian T.N., Castillo V., and Goldberg A.L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol. Cell 4 3 (1999) 395-402
19. Navon A., and Goldberg A.L. Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome. Mol. Cell 8 6 (2001) 1339-1349
20. Voges D., Zwickl P., and Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68 (1999) 1015-1068
21. Liu C.W., Corboy M.J., DeMartino G.N., and Thomas P.J. Endoproteolytic activity of the proteasome. Science 299 5605 (2003) 408-411
22. DeMartino G.N., and Slaughter C.A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274 32 (1999) 22123-22126
23. Ortega J., Heymann J.B., Kajava A.V., Ustrell V., Rechsteiner M., and Steven A.C. The axial channel of the 20S proteasome opens upon binding of the PA200 activator. J. Mol. Biol. 346 5 (2005) 1221-1227
24. Rechsteiner M., and Hill C.P. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol. 15 1 (2005) 27-33
25. Coux O., Tanaka K., and Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 65 (1996) 801-847
26. Smith D.M., Benaroudj N., and Goldberg A. Proteasomes and their associated ATPases: a destructive combination. J. Struct. Biol. 156 1 (2006) 72-83
27. Cascio P., Call M., Petre B.M., Walz T., and Goldberg A.L. Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J. 21 11 (2002) 2636-2645
28. Reits E.A., Benham A.M., Plougastel B., Neefjes J., and Trowsdale J. Dynamics of proteasome distribution in living cells. EMBO J. 16 20 (1997) 6087-6094
29. Wojcik C., and DeMartino G.N. Intracellular localization of proteasomes. Int. J. Biochem. Cell Biol. 35 5 (2003) 579-589
30. Baldin V., Militello M., Thomas Y., Doucet C., Fic W., Boireau S., et al. A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking. Mol. Biol. Cell 19 4 (2008) 1706-1716
31. Furukawa Y., Vigouroux S., Wong H., Guttman M., Rajput A.H., Ang L., et al. Brain proteasomal function in sporadic Parkinson's disease and related disorders. Ann. Neurol. 51 6 (2002) 779-782
32. McNaught K.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179 1 (2003) 38-46
33. McNaught K.S., and Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297 3 (2001) 191-194
34. Tofaris G.K., Razzaq A., Ghetti B., Lilley K.S., and Spillantini M.G. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278 45 (2003) 44405-44411
35. McNaught K.S., Belizaire R., Jenner P., Olanow C.W., and Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326 3 (2002) 155-158
36. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., and Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295 5556 (2002) 865-868
37. Ii K., Ito H., Tanaka K., and Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J. Neuropathol. Exp. Neurol. 56 2 (1997) 125-131
38. Lennox G., Lowe J., Morrell K., Landon M., and Mayer R.J. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J. Neurol. Neurosurg. Psychiatry 52 1 (1989) 67-71
39. Lowe J., McDermott H., Landon M., Mayer R.J., and Wilkinson K.D. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J. Pathol. 161 2 (1990) 153-160
40. McNaught K.S., Shashidharan P., Perl D.P., Jenner P., and Olanow C.W. Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci. 16 11 (2002) 2136-2148
41. Schlossmacher M.G., Frosch M.P., Gai W.P., Medina M., Sharma N., Forno L., et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160 5 (2002) 1655-1667
42. McNaught K.S., Mytilineou C., Jnobaptiste R., Yabut J., Shashidharan P., Jennert P., et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem. 81 2 (2002) 301-306
43. Rideout H.J., Lang-Rollin I.C., Savalle M., and Stefanis L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem. 93 5 (2005) 1304-1313
44. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56 1 (2004) 149-162
45. McNaught K.S., and Olanow C.W. Proteasome inhibitor-induced model of Parkinson's disease. Ann. Neurol. 60 2 (2006) 243-247
46. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., et al. Proteasome inhibition and Parkinson's disease modeling. Ann. Neurol. 60 2 (2006) 260-264
47. Hawlitschka A., Haas S.J., Schmitt O., Weiss D.G., and Wree A. Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats. Brain Res. 1173 (2007) 137-144
48. Kordower J.H., Kanaan N.M., Chu Y., Suresh Babu R., Stansell III J., Terpstra B.T., et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann. Neurol. 60 2 (2006) 264-268
49. Manning-Bog A.B., Reaney S.H., Chou V.P., Johnston L.C., McCormack A.L., Johnston J., et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann. Neurol. 60 2 (2006) 256-260
50. Schapira A.H., Cleeter M.W., Muddle J.R., Workman J.M., Cooper J.M., and King R.H. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann. Neurol. 60 2 (2006) 253-255
51. Zeng B.Y., Bukhatwa S., Hikima A., Rose S., and Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann. Neurol. 60 2 (2006) 248-252
52. Bedford L., Hay D., Devoy A., Paine S., Powe D.G., Seth R., et al. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 28 33 (2008) 8189-8198
53. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22 2 (2006) 404-420
54. Wang C., Ko H.S., Thomas B., Tsang F., Chew K.C., Tay S.P., et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. 14 24 (2005) 3885-3897
55. Wang X.F., Li S., Chou A.P., and Bronstein J.M. Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease. Neurobiol. Dis. 23 1 (2006) 198-205
56. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 102 9 (2005) 3413-3418
57. Zeng B.Y., Iravani M.M., Lin S.T., Irifune M., Kuoppamaki M., Al-Barghouthy G., et al. MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome. Eur. J. Neurosci. 23 7 (2006) 1766-1774
58. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., and Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. NeuroReport 11 1 (2000) 211-213
59. Hardy J., Cookson M.R., and Singleton A. Genes and parkinsonism. Lancet Neurol. 2 4 (2003) 221-228
60. Maroteaux L., Campanelli J.T., and Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8 8 (1988) 2804-2815
61. Davidson W.S., Jonas A., Clayton D.F., and George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273 16 (1998) 9443-9449
62. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 1 (2000) 239-252
63. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIlwain K.L., et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22 20 (2002) 8797-8807
64. Murphy D.D., Rueter S.M., Trojanowski J.Q., and Lee V.M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20 9 (2000) 3214-3220
65. Yavich L., Jakala P., and Tanila H. Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice. J. Neurochem. 99 3 (2006) 724-732
66. Yavich L., Tanila H., Vepsalainen S., and Jakala P. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 24 49 (2004) 11165-11170
67. Fortin D.L., Nemani V.M., Voglmaier S.M., Anthony M.D., Ryan T.A., and Edwards R.H. Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci. 25 47 (2005) 10913-10921
68. Fortin D.L., Troyer M.D., Nakamura K., Kubo S., Anthony M.D., and Edwards R.H. Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24 30 (2004) 6715-6723
69. Jia J.M., Chen Q., Zhou Y., Miao S., Zheng J., Zhang C., et al. Brain-derived neurotrophic factor-tropomyosin-related kinase B signaling contributes to activity-dependent changes in synaptic proteins. J. Biol. Chem. 283 30 (2008) 21242-21250
70. Bozzi Y., Pizzorusso T., Cremisi F., Rossi F.M., Barsacchi G., and Maffei L. Monocular deprivation decreases the expression of messenger RNA for brain-derived neurotrophic factor in the rat visual cortex. Neuroscience 69 4 (1995) 1133-1144
71. Hardingham G.E., Fukunaga Y., and Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5 5 (2002) 405-414
72. Isackson P.J., Huntsman M.M., Murray K.D., and Gall C.M. BDNF mRNA expression is increased in adult rat forebrain after limbic seizures: temporal patterns of induction distinct from NGF. Neuron 6 6 (1991) 937-948
73. Zafra F., Castren E., Thoenen H., and Lindholm D. Interplay between glutamate and gamma-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 88 22 (1991) 10037-10041
74. Lee H.J., Choi C., and Lee S.J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277 1 (2002) 671-678
75. Dluzen D.E., McDermott J.L., Anderson L.I., Kucera J., Joyce J.N., Osredkar T., et al. Age-related changes in nigrostriatal dopaminergic function are accentuated in +/- brain-derived neurotrophic factor mice. Neuroscience 128 1 (2004) 201-208
76. Chen L., and Feany M.B. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8 5 (2005) 657-663
77. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4 2 (2002) 160-164
78. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 5493 (2000) 985-989
79. Giasson B.I., Forman M.S., Higuchi M., Golbe L.I., Graves C.L., Kotzbauer P.T., et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300 5619 (2003) 636-640
80. Giasson B.I., Uryu K., Trojanowski J.Q., and Lee V.M. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274 12 (1999) 7619-7622
81. Hodara R., Norris E.H., Giasson B.I., Mishizen-Eberz A.J., Lynch D.R., Lee V.M., et al. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 279 46 (2004) 47746-47753
82. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. U. S. A. 102 6 (2005) 2162-2167
83. Mishizen-Eberz A.J., Norris E.H., Giasson B.I., Hodara R., Ischiropoulos H., Lee V.M., et al. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44 21 (2005) 7818-7829
84. Murray I.V., Giasson B.I., Quinn S.M., Koppaka V., Axelsen P.H., Ischiropoulos H., et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42 28 (2003) 8530-8540
85. Norris E.H., Giasson B.I., Ischiropoulos H., and Lee V.M. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem. 278 29 (2003) 27230-27240
86. Singleton A., and Gwinn-Hardy K. Parkinson's disease and dementia with Lewy bodies: a difference in dose?. Lancet 364 9440 (2004) 1105-1107
87. Smith W.W., Margolis R.L., Li X., Troncoso J.C., Lee M.K., Dawson V.L., et al. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25 23 (2005) 5544-5552
88. Tofaris G.K., Garcia Reitbock P., Humby T., Lambourne S.L., O'Connell M., Ghetti B., et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J. Neurosci. 26 15 (2006) 3942-3950
89. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280 22 (2005) 21212-21219
90. Serpell L.C., Berriman J., Jakes R., Goedert M., and Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. U. S. A. 97 9 (2000) 4897-4902
91. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport 10 4 (1999) 717-721
92. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281 40 (2006) 29739-29752
93. Waxman E.A., and Giasson B.I. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 67 5 (2008) 402-416
94. Arawaka S., Wada M., Goto S., Karube H., Sakamoto M., Ren C.H., et al. The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J. Neurosci. 26 36 (2006) 9227-9238
95. Okochi M., Walter J., Koyama A., Nakajo S., Baba M., Iwatsubo T., et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275 1 (2000) 390-397
96. Paleologou K.E., Schmid A.W., Rospigliosi C.C., Kim H.Y., Lamberto G.R., Fredenburg R.A., et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 283 24 (2008) 16895-16905
97. Pronin A.N., Morris A.J., Surguchov A., and Benovic J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275 34 (2000) 26515-26522
98. Liu C., Fei E., Jia N., Wang H., Tao R., Iwata A., et al. Assembly of lysine 63-linked ubiquitin conjugates by phosphorylated alpha-synuclein implies Lewy body biogenesis. J. Biol. Chem. 282 19 (2007) 14558-14566
99. Sugeno N., Takeda A., Hasegawa T., Kobayashi M., Kikuchi A., Mori F., et al. Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J. Biol. Chem. 283 34 (2008) 23179-23188
100. Gorbatyuk O.S., Li S., Sullivan L.F., Chen W., Kondrikova G., Manfredsson F.P., et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 105 2 (2008) 763-768
101. Lee J.T., Wheeler T.C., Li L., and Chin L.S. Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum. Mol. Genet. 17 6 (2008) 906-917
102. Rott R., Szargel R., Haskin J., Shani V., Shainskaya A., Manov I., et al. Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J. Biol. Chem. 283 6 (2008) 3316-3328
103. Lee G., Junn E., Tanaka M., Kim Y.M., and Mouradian M.M. Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival. J. Neurochem. 83 2 (2002) 346-352
104. Liani E., Eyal A., Avraham E., Shemer R., Szargel R., Berg D., et al. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 15 (2004) 5500-5505
105. Marx F.P., Soehn A.S., Berg D., Melle C., Schiesling C., Lang M., et al. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein-implications for Parkinson's disease. Faseb. J. 21 8 (2007) 1759-1767
106. Avraham E., Szargel R., Eyal A., Rott R., and Engelender S. Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation. J. Biol. Chem. 280 52 (2005) 42877-42886
107. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152 4 (1998) 879-884
108. Campbell B.C., McLean C.A., Culvenor J.G., Gai W.P., Blumbergs P.C., Jakala P., et al. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 76 1 (2001) 87-96
109. Crowther R.A., Jakes R., Spillantini M.G., and Goedert M. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436 3 (1998) 309-312
110. Cappai R., Leck S.L., Tew D.J., Williamson N.A., Smith D.P., Galatis D., et al. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 19 10 (2005) 1377-1379
111. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 5545 (2001) 1346-1349
112. Li J., Zhu M., Manning-Bog A.B., Di Monte D.A., and Fink A.L. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J. 18 9 (2004) 962-964
113. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., and Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 6 (2002) 600-606
114. Mazzulli J.R., Mishizen A.J., Giasson B.I., Lynch D.R., Thomas S.A., Nakashima A., et al. Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26 39 (2006) 10068-10078
115. Mazzulli J.R., Armakola M., Dumoulin M., Parastatidis I., and Ischiropoulos H. Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J. Biol. Chem. 282 43 (2007) 31621-31630
116. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., and Mouradian M.M. Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274 48 (1999) 33855-33858
117. Ancolio K., Alves da Costa C., Ueda K., and Checler F. Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 285 2 (2000) 79-82
118. Dufty B.M., Warner L.R., Hou S.T., Jiang S.X., Gomez-Isla T., Leenhouts K.M., et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 170 5 (2007) 1725-1738
119. Kim H.J., Lee D., Lee C.H., Chung K.C., Kim J., and Paik S.R. Calpain-resistant fragment(s) of alpha-synuclein regulates the synuclein-cleaving activity of 20S proteasome. Arch. Biochem. Biophys. 455 1 (2006) 40-47
120. Cole N.B., Murphy D.D., Lebowitz J., Di Noto L., Levine R.L., and Nussbaum R.L. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J. Biol. Chem. 280 10 (2005) 9678-9690
121. Tofaris G.K., Layfield R., and Spillantini M.G. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509 1 (2001) 22-26
122. Liu C.W., Giasson B.I., Lewis K.A., Lee V.M., Demartino G.N., and Thomas P.J. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280 24 (2005) 22670-22678
123. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G., and Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273 41 (1998) 26292-26294
124. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 10 Suppl (2004) S18-25
125. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10 9 (2001) 919-926
126. Martin-Clemente B., Alvarez-Castelao B., Mayo I., Sierra A.B., Diaz V., Milan M., et al. alpha-Synuclein expression levels do not significantly affect proteasome function and expression in mice and stably transfected PC12 cell lines. J. Biol. Chem. 279 51 (2004) 52984-52990
127. Fujita M., Sugama S., Nakai M., Takenouchi T., Wei J., Urano T., et al. alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity. J. Biol. Chem. 282 8 (2007) 5736-5748
128. Sun F., Anantharam V., Latchoumycandane C., Kanthasamy A., and Kanthasamy A.G. Dieldrin induces ubiquitin-proteasome dysfunction in alpha-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death. J. Pharmacol. Exp. Ther. 315 1 (2005) 69-79
129. Bodner R.A., Outeiro T.F., Altmann S., Maxwell M.M., Cho S.H., Hyman B.T., et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl. Acad. Sci. U. S. A. 103 11 (2006) 4246-4251
130. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36 6 (2002) 1007-1019
131. Chen Q., Thorpe J., and Keller J.N. Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J. Biol. Chem. 280 34 (2005) 30009-30017
132. Gallardo G., Schluter O.M., and Sudhof T.C. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat. Neurosci. 11 3 (2008) 301-308
133. Emmanouilidou E., Stefanis L., and Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging (2008)
134. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 279 13 (2004) 12924-12934
135. Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., and Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278 14 (2003) 11753-11759
136. Zhang N.Y., Tang Z., and Liu C.W. alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J. Biol. Chem. 283 29 (2008) 20288-20298
137. Ghee M., Fournier A., and Mallet J. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 75 5 (2000) 2221-2224
138. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 5618 (2003) 486-489
139. Tseng B.P., Green K.N., Chan J.L., Blurton-Jones M., and Laferla F.M. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging 29 11 (2008) 1607-1618
140. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 5521 (2001) 1552-1555
141. Bennett E.J., Bence N.F., Jayakumar R., and Kopito R.R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell 17 3 (2005) 351-365
142. Bennett E.J., Shaler T.A., Woodman B., Ryu K.Y., Zaitseva T.S., Becker C.H., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 448 7154 (2007) 704-708
143. Jana N.R., Zemskov E.A., Wang G., and Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 10 10 (2001) 1049-1059
144. Verhoef L.G., Lindsten K., Masucci M.G., and Dantuma N.P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum. Mol. Genet. 11 22 (2002) 2689-2700
145. Kristiansen M., Deriziotis P., Dimcheff D.E., Jackson G.S., Ovaa H., Naumann H., et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol. Cell 26 2 (2007) 175-188
146. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 99 13 (2002) 8968-8973
147. Hattori N., Shimura H., Kubo S., Wang M., Shimizu N., Tanaka K., et al. Importance of familial Parkinson's disease and parkinsonism to the understanding of nigral degeneration in sporadic Parkinson's disease. J. Neural Transm., Suppl. 60 (2000) 101-116
148. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342 21 (2000) 1560-1567
149. Mata I.F., Lockhart P.J., and Farrer M.J. Parkin genetics: one model for Parkinson's disease. Hum. Mol. Genet. 13 Spec No 1 (2004) R127-R133
150. Hayashi S., Wakabayashi K., Ishikawa A., Nagai H., Saito M., Maruyama M., et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov. Disord. 15 5 (2000) 884-888
151. Mori H., Kondo T., Yokochi M., Matsumine H., Nakagawa-Hattori Y., Miyake T., et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51 3 (1998) 890-892
152. Takahashi H., Ohama E., Suzuki S., Horikawa Y., Ishikawa A., Morita T., et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44 3 Pt 1 (1994) 437-441
153. van de Warrenburg B.P., Lammens M., Lucking C.B., Denefle P., Wesseling P., Booij J., et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56 4 (2001) 555-557
154. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., and Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105 7 (2001) 891-902
155. Staropoli J.F., McDermott C., Martinat C., Schulman B., Demireva E., and Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37 5 (2003) 735-749
156. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 5528 (2001) 263-269
157. Choi P., Golts N., Snyder H., Chong M., Petrucelli L., Hardy J., et al. Co-association of parkin and alpha-synuclein. NeuroReport 12 13 (2001) 2839-2843
158. Kawahara K., Hashimoto M., Bar-On P., Ho G.J., Crews L., Mizuno H., et al. alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease. J. Biol. Chem. 283 11 (2008) 6979-6987
159. Choi P., Ostrerova-Golts N., Sparkman D., Cochran E., Lee J.M., and Wolozin B. Parkin is metabolized by the ubiquitin/proteosome system. Neuroreport 11 12 (2000) 2635-2638
160. Kahle P.J., and Haass C. How does parkin ligate ubiquitin to Parkinson's disease?. EMBO Rep. 5 7 (2004) 681-685
161. Snyder H., and Wolozin B. Pathological proteins in Parkinson's disease: focus on the proteasome. J. Mol. Neurosci. 24 3 (2004) 425-442
162. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., and Dawson T.M. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U. S. A. 97 24 (2000) 13354-13359
163. Springer W., Hoppe T., Schmidt E., and Baumeister R. A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum. Mol. Genet. 14 22 (2005) 3407-3423
164. Schlehe J.S., Lutz A.K., Pilsl A., Lammermann K., Grgur K., Henn I.H., et al. Aberrant folding of pathogenic Parkin mutants: aggregation versus degradation. J. Biol. Chem. 283 20 (2008) 13771-13779
165. Wang C., Tan J.M., Ho M.W., Zaiden N., Wong S.H., Chew C.L., et al. Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. J. Neurochem. 93 2 (2005) 422-431
166. Chung K.K., Thomas B., Li X., Pletnikova O., Troncoso J.C., Marsh L., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304 5675 (2004) 1328-1331
167. Pawlyk A.C., Giasson B.I., Sampathu D.M., Perez F.A., Lim K.L., Dawson V.L., et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem. 278 48 (2003) 48120-48128
168. Darios F., Corti O., Lucking C.B., Hampe C., Muriel M.P., Abbas N., et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 12 5 (2003) 517-526
169. Higashi Y., Asanuma M., Miyazaki I., Hattori N., Mizuno Y., and Ogawa N. Parkin attenuates manganese-induced dopaminergic cell death. J. Neurochem. 89 6 (2004) 1490-1497
170. Imai Y., Soda M., and Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275 46 (2000) 35661-35664
171. Jiang H., Ren Y., Zhao J., and Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet. 13 16 (2004) 1745-1754
172. Ko H.S., von Coelln R., Sriram S.R., Kim S.W., Chung K.K., Pletnikova O., et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 25 35 (2005) 7968-7978
173. Ledesma M.D., Galvan C., Hellias B., Dotti C., and Jensen P.H. Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress. J. Neurochem. 83 6 (2002) 1431-1440
174. Tsai Y.C., Fishman P.S., Thakor N.V., and Oyler G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 278 24 (2003) 22044-22055
175. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 6 (2003) 911-924
176. Whitworth A.J., Theodore D.A., Greene J.C., Benes H., Wes P.D., and Pallanck L.J. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 102 22 (2005) 8024-8029
177. Zhou W., and Freed C.R. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J. Biol. Chem. 280 52 (2005) 43150-43158
178. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., and Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11 11 (2005) 1214-1221
179. Yu L.Y., Saarma M., and Arumae U. Death receptors and caspases but not mitochondria are activated in the GDNF- or BDNF-deprived dopaminergic neurons. J. Neurosci. 28 30 (2008) 7467-7475
180. Kahns S., Kalai M., Jakobsen L.D., Clark B.F., Vandenabeele P., and Jensen P.H. Caspase-1 and caspase-8 cleave and inactivate cellular parkin. J. Biol. Chem. 278 26 (2003) 23376-23380
181. Chauhan N.B., Siegel G.J., and Lee J.M. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J. Chem. Neuroanat. 21 4 (2001) 277-288
182. Siegel G.J., and Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Brain Res. Rev. 33 2-3 (2000) 199-227
183. Weinreb O., Amit T., Bar-Am O., and Youdim M.B. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. N.Y. Acad. Sci. 1122 (2007) 155-168
184. Shimura H., Hattori N., Kubo S., Yoshikawa M., Kitada T., Matsumine H., et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45 5 (1999) 668-672
185. Taira T., Saito Y., Niki T., Iguchi-Ariga S.M., Takahashi K., and Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5 2 (2004) 213-218
186. Takahashi K., Taira T., Niki T., Seino C., Iguchi-Ariga S.M., and Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J. Biol. Chem. 276 40 (2001) 37556-37563
187. Xu J., Zhong N., Wang H., Elias J.E., Kim C.Y., Woldman I., et al. The Parkinson's disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum. Mol. Genet. 14 9 (2005) 1231-1241
188. Zhong N., Kim C.Y., Rizzu P., Geula C., Porter D.R., Pothos E.N., et al. DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J. Biol. Chem. 281 30 (2006) 20940-20948
189. Abou-Sleiman P.M., Healy D.G., Quinn N., Lees A.J., and Wood N.W. The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54 3 (2003) 283-286
190. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 5604 (2003) 256-259
191. Clark L.N., Afridi S., Mejia-Santana H., Harris J., Louis E.D., Cote L.J., et al. Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations. Mov. Disord. 19 7 (2004) 796-800
192. Hague S., Rogaeva E., Hernandez D., Gulick C., Singleton A., Hanson M., et al. Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann. Neurol. 54 2 (2003) 271-274
193. Shendelman S., Jonason A., Martinat C., Leete T., and Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2 11 (2004) e362
194. Martinat C., Shendelman S., Jonason A., Leete T., Beal M.F., Yang L., et al. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES-derived cell model of primary Parkinsonism. PLoS Biol. 2 11 (2004) e327
195. Yokota T., Sugawara K., Ito K., Takahashi R., Ariga H., and Mizusawa H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem. Biophys. Res. Commun. 312 4 (2003) 1342-1348
196. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36 3 (1994) 348-355
197. Burwell L.S., Nadtochiy S.M., Tompkins A.J., Young S., and Brookes P.S. Direct evidence for S-nitrosation of mitochondrial complex I. Biochem. J. 394 Pt 3 (2006) 627-634
198. Chinta S.J., Kumar M.J., Hsu M., Rajagopalan S., Kaur D., Rane A., et al. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J. Neurosci. 27 51 (2007) 13997-14006
199. Chinta S.J., Rajagopalan S., Butterfield D.A., and Andersen J.K. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci. Lett. 402 1-2 (2006) 137-141
200. Hsu M., Srinivas B., Kumar J., Subramanian R., and Andersen J. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. J. Neurochem. 92 5 (2005) 1091-1103
201. Kwak M.K., Wakabayashi N., Greenlaw J.L., Yamamoto M., and Kensler T.W. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol. Cell. Biol. 23 23 (2003) 8786-8794
202. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236 2 (1997) 313-322
203. Kwak M.K., Itoh K., Yamamoto M., Sutter T.R., and Kensler T.W. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol. Med. 7 2 (2001) 135-145
204. Thimmulappa R.K., Mai K.H., Srisuma S., Kensler T.W., Yamamoto M., and Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62 18 (2002) 5196-5203
205. Wasserman W.W., and Fahl W.E. Functional antioxidant responsive elements. Proc. Natl. Acad. Sci. U. S. A. 94 10 (1997) 5361-5366
206. Itoh K., Wakabayashi N., Katoh Y., Ishii T., Igarashi K., Engel J.D., et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13 1 (1999) 76-86
207. Clements C.M., McNally R.S., Conti B.J., Mak T.W., and Ting J.P. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl. Acad. Sci. U. S. A. 103 41 (2006) 15091-15096
208. Stewart D., Killeen E., Naquin R., Alam S., and Alam J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J. Biol. Chem. 278 4 (2003) 2396-2402
209. Yang W., Chen L., Ding Y., Zhuang X., and Kang U.J. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum. Mol. Genet. 16 23 (2007) 2900-2910
210. Alegre-Abarrategui J., Ansorge O., Esiri M., and Wade-Martins R. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol. Appl. Neurobiol. 34 3 (2008) 272-283
211. Perry G., Zhu X., Babar A.K., Siedlak S.L., Yang Q., Ito G., et al. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Neurodegener. Dis. 5 3-4 (2008) 222-224
212. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., and Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51 3 (2002) 296-301
213. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 9457 (2005) 415-416
214. Rajput A., Dickson D.W., Robinson C.A., Ross O.A., Dachsel J.C., Lincoln S.J., et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67 8 (2006) 1506-1508
215. Gaig C., Marti M.J., Ezquerra M., Rey M.J., Cardozo A., and Tolosa E. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J. Neurol. Neurosurg. Psychiatry 78 6 (2007) 626-628
216. Beach T.G., Walker D.G., Sue L.I., Newell A., Adler C.C., and Joyce J.N. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J. Neuropathol. Exp. Neurol. 63 4 (2004) 329-337
217. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 102 51 (2005) 18676-18681
218. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15 2 (2006) 223-232
219. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 46 (2005) 16842-16847
220. Wang L., Xie C., Greggio E., Parisiadou L., Shim H., Sun L., et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci. 28 13 (2008) 3384-3391
221. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 129 Pt 7 (2006) 1720-1731
222. Muqit M.M., Abou-Sleiman P.M., Saurin A.T., Harvey K., Gandhi S., Deas E., et al. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J. Neurochem. 98 1 (2006) 156-169
223. Silvestri L., Caputo V., Bellacchio E., Atorino L., Dallapiccola B., Valente E.M., et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 14 22 (2005) 3477-3492
224. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 5674 (2004) 1158-1160
225. Grunewald A., Breedveld G.J., Lohmann-Hedrich K., Rohe C.F., Konig I.R., Hagenah J., et al. Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. Neurogenetics 8 2 (2007) 103-109
226. Beilina A., Van Der Brug M., Ahmad R., Kesavapany S., Miller D.W., Petsko G.A., et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl. Acad. Sci. U. S. A. 102 16 (2005) 5703-5708
227. Sim C.H., Lio D.S., Mok S.S., Masters C.L., Hill A.F., Culvenor J.G., et al. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum. Mol. Genet. 15 21 (2006) 3251-3262
228. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441 7097 (2006) 1162-1166
229. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 7097 (2006) 1157-1161
230. Greene J.C., Whitworth A.J., Kuo I., Andrews L.A., Feany M.B., and Pallanck L.J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. U. S. A. 100 7 (2003) 4078-4083
231. Pesah Y., Pham T., Burgess H., Middlebrooks B., Verstreken P., Zhou Y., et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131 9 (2004) 2183-2194
232. Wood-Kaczmar A., Gandhi S., Yao Z., Abramov A.S., Miljan E.A., Keen G., et al. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS ONE 3 6 (2008) e2455
233. Petit A., Kawarai T., Paitel E., Sanjo N., Maj M., Scheid M., et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem. 280 40 (2005) 34025-34032
234. Wang H.L., Chou A.H., Yeh T.H., Li A.H., Chen Y.L., Kuo Y.L., et al. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol. Dis. 28 2 (2007) 216-226
235. Abou-Sleiman P.M., Muqit M.M., McDonald N.Q., Yang Y.X., Gandhi S., Healy D.G., et al. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann. Neurol. 60 4 (2006) 414-419
236. Valente E.M., Salvi S., Ialongo T., Marongiu R., Elia A.E., Caputo V., et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56 3 (2004) 336-341